Figure Legends
Figure 1. Clinical course of the patient. DAH, daunorubicin (40 mg/m2), cytosine arabinoside (100mg/m2), homoharringtonine (3 mg/m2); IAH, idarubicin (10 mg/m2), cytosine arabinoside (100mg/m2), homoharringtonine (3 mg/m2); DCAG, decitabine (20 mg/m2), aclacinomycin (10 mg/m2), cytosine arabinoside (10 mg/m2), granulocyte-colony stimulating factor (125μg).